BR112014009144A2 - avaliação do risco de pml e métodos com base na mesma - Google Patents

avaliação do risco de pml e métodos com base na mesma

Info

Publication number
BR112014009144A2
BR112014009144A2 BR112014009144A BR112014009144A BR112014009144A2 BR 112014009144 A2 BR112014009144 A2 BR 112014009144A2 BR 112014009144 A BR112014009144 A BR 112014009144A BR 112014009144 A BR112014009144 A BR 112014009144A BR 112014009144 A2 BR112014009144 A2 BR 112014009144A2
Authority
BR
Brazil
Prior art keywords
treatment
risk assessment
methods based
pml
same
Prior art date
Application number
BR112014009144A
Other languages
English (en)
Other versions
BR112014009144A8 (pt
Inventor
Wiendl Heinz
Schwab Nicholas
Schneider-Hohendorf Tilman
Original Assignee
Westfaelische Wilhelms-Universitaet Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westfaelische Wilhelms-Universitaet Muenster filed Critical Westfaelische Wilhelms-Universitaet Muenster
Publication of BR112014009144A2 publication Critical patent/BR112014009144A2/pt
Publication of BR112014009144A8 publication Critical patent/BR112014009144A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "avaliação do risco de pml e métodos com base na mesma". a presente invenção fornece um método para avaliação do risco de ocorrência de leucoencefalopatia multifocal progressiva (progressive multifocal leukoencephalopathy - pml) em um indivíduo, bem como um método de estratificação de um indivíduo que está recebendo tratamento com agente de bloqueio de ?4-integrina e/ou tratamento com agente de bloqueio de vla-4 para suspensão do tratamento e um método de estratificação de um indivíduo que está recebendo terapia antirretroviral altamente ativa (haart) para alteração de haart. estes métodos compreendem detecção do nível de células t que expressam ligante-1 de glicoproteína p-selectina (psgl-1) em uma amostra do indivíduo.
BR112014009144A 2011-10-17 2012-10-16 avaliação do risco de pml e métodos com base na mesma BR112014009144A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11185439 2011-10-17
EP12158369 2012-03-07
PCT/EP2012/070472 WO2013057096A1 (en) 2011-10-17 2012-10-16 Assessment of pml risk and methods based thereon

Publications (2)

Publication Number Publication Date
BR112014009144A2 true BR112014009144A2 (pt) 2017-06-13
BR112014009144A8 BR112014009144A8 (pt) 2017-06-20

Family

ID=47215496

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014009144A BR112014009144A8 (pt) 2011-10-17 2012-10-16 avaliação do risco de pml e métodos com base na mesma
BR112014009310A BR112014009310A2 (pt) 2011-10-17 2012-10-16 métodos de avaliação de riscos de lmp e aparelhos relacionados

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014009310A BR112014009310A2 (pt) 2011-10-17 2012-10-16 métodos de avaliação de riscos de lmp e aparelhos relacionados

Country Status (7)

Country Link
US (1) US20150105278A1 (pt)
EP (2) EP2769223A1 (pt)
AU (2) AU2012325013A1 (pt)
BR (2) BR112014009144A8 (pt)
CA (2) CA2850885A1 (pt)
MX (2) MX2014004025A (pt)
WO (2) WO2013057092A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035098T2 (en) 2010-04-16 2018-05-02 Biogen Ma Inc Anti-VLA4 Antibodies
US20160152709A1 (en) * 2013-07-05 2016-06-02 Biogen Ma Inc. Compositions and methods for treatment of stroke
WO2015042254A1 (en) * 2013-09-18 2015-03-26 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
EP3757224A3 (en) * 2014-02-27 2021-03-17 Biogen MA Inc. Method of assessing risk of pml
WO2017134178A1 (en) * 2016-02-05 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Imaging method for predicting the onset of multiple sclerosis
WO2018140510A1 (en) * 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
DK0914605T3 (da) 1996-07-25 2007-09-10 Biogen Idec Inc Molekylemodel for VLA-4-inhibitorer
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
DK0991619T3 (da) 1997-06-23 2003-12-29 Tanabe Seiyaku Co Inhibitorer af alfa 4-beta 1-medieret celleadhæsion
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
JP3180906B2 (ja) 1998-11-12 2001-07-03 日本電気株式会社 磁気抵抗効果型複合ヘッドの製造方法
CZ20012980A3 (cs) 1999-02-18 2002-04-17 F. Hoffmann-La Roche Ag Thioamidové deriváty
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
JP4788939B2 (ja) 1999-11-18 2011-10-05 味の素株式会社 新規フェニルアラニン誘導体
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
BR0016818A (pt) 1999-12-28 2002-10-01 Pfizer Prod Inc Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias
EP1270547A4 (en) 2000-03-23 2005-07-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
WO2002008206A1 (en) 2000-07-21 2002-01-31 Elan Pharmaceuticals, Inc. 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
US7015216B2 (en) 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
CN1325480C (zh) 2000-08-18 2007-07-11 味之素株式会社 苯基丙氨酸衍生物
SI1370531T1 (sl) 2001-02-22 2007-08-31 Ucb Pharma Sa Derivati fenilalanin enamida s ciklobutensko skupino, za uporabo kot integrin inhibitorji
US20030077576A1 (en) * 2001-03-20 2003-04-24 Joann Trial Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2002354224A1 (en) 2001-12-13 2003-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
GB0216571D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
GB0216568D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
US7446125B2 (en) 2003-04-09 2008-11-04 Universidad Del Pais Vasco Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders
JP4430076B2 (ja) 2003-10-01 2010-03-10 イーティーエイチ・チューリッヒ ポリペプチドの試験管内進化方法
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2008097190A1 (en) 2007-02-05 2008-08-14 Agency For Science, Technology And Research Methods of electrically detecting a nucleic acid by means of an electrode pair
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2009041917A1 (en) 2007-09-28 2009-04-02 Agency For Science, Technology And Research Method of electrically detecting a nucleic acid molecule
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
EP2226392A1 (en) * 2009-03-03 2010-09-08 Assistance Publique - Hôpitaux de Paris Method for detecting JCV infection
CN103874503A (zh) 2010-12-21 2014-06-18 瑟莱克斯制药公司 抗p-选择素抗体及其使用和鉴定方法

Also Published As

Publication number Publication date
CA2850885A1 (en) 2013-04-25
EP2769223A1 (en) 2014-08-27
WO2013057092A1 (en) 2013-04-25
WO2013057096A1 (en) 2013-04-25
AU2012325017A1 (en) 2014-04-17
MX2014004319A (es) 2015-05-15
BR112014009144A8 (pt) 2017-06-20
AU2012325013A1 (en) 2014-03-27
BR112014009310A2 (pt) 2017-04-11
EP2769222A1 (en) 2014-08-27
CA2848587A1 (en) 2013-04-25
US20150105278A1 (en) 2015-04-16
MX2014004025A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
BR112014009144A2 (pt) avaliação do risco de pml e métodos com base na mesma
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112012028452A2 (pt) dispositivos e métodos para avaliar mudanças na saúde da córnea
CY1121981T1 (el) Μεθοδος για τον προσδιορισμο κινδυνου pml
BR112014029588A2 (pt) sistema e métodos para detectar distúrbios de saúde
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
BR112014018970A8 (pt) Dispositivos de coleta de amostra com agentes de estabilização sanguínea
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
AR082388A1 (es) Metodo para identificar un compuesto que tiene un efecto antiarritmico asi como los usos relacionados con el mismo
BR112016001957A2 (pt) biossensor
BR112013022234A2 (pt) emulsão de dodecafluorpentano como uma terapia de acidente vascular cerebral e isquemia
BR112013019278A2 (pt) método e sistema para prover um usuário com uma sessão de usuário, e meio legível por computador não transitório que contém instruções de programa de software.
MX356797B (es) Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.
PE20141565A1 (es) Metodos para detectar papilomavirus humano y proporcionar pronostico para carcinoma de celulas escamosas de cabeza y cuello
MX2017010569A (es) Dispositivo, plataforma y ensayo para evaluacion de celulas.
BR112013030122A2 (pt) método para simular uma resposta de um instrumento de perfilagem de poço de nêutrons, meio legível por computador não transitório, e método para perfilagem de poço
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
MX2015001717A (es) Metodo para la deteccion directa de mycobacterium tuberculosis.
EP2738689A4 (en) SYSTEM FOR GENERATING A DISPLAY OF INFORMATION RESISTANT INDEX, INDEX GENERATING DEVICE AND METHOD THEREFOR
BR112015017815A2 (pt) método para prever o início dos sintomas extrapiramidais (eps) induzidos por um tratamento a base de antipsicótico
GB201200178D0 (en) Diagnostic method and system
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.
AR085164A1 (es) Metodos para el analisis de la placa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]